These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 28938966)
1. High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Waksman R; Bakris GL; Steinvil A; Garcia-Garcia H; Brown AL; DiFilippo W; Scott T; Singh J; DeBruin V; Jones D; Jolivette D; Bhatt DL Am Heart J; 2017 Oct; 192():76-84. PubMed ID: 28938966 [TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Bhatt DL; Vaduganathan M; Kandzari DE; Leon MB; Rocha-Singh K; Townsend RR; Katzen BT; Oparil S; Brar S; DeBruin V; Fahy M; Bakris GL; Lancet; 2022 Oct; 400(10361):1405-1416. PubMed ID: 36130612 [TBL] [Abstract][Full Text] [Related]
3. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Bakris GL; Townsend RR; Flack JM; Brar S; Cohen SA; D'Agostino R; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL; J Am Coll Cardiol; 2015 Apr; 65(13):1314-1321. PubMed ID: 25835443 [TBL] [Abstract][Full Text] [Related]
4. SYMPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients - . Kario K; Ogawa H; Okumura K; Okura T; Saito S; Ueno T; Haskin R; Negoita M; Shimada K; Circ J; 2015; 79(6):1222-9. PubMed ID: 25912693 [TBL] [Abstract][Full Text] [Related]
5. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Fadl Elmula FE; Hoffmann P; Larstorp AC; Fossum E; Brekke M; Kjeldsen SE; Gjønnæss E; Hjørnholm U; Kjaer VN; Rostrup M; Os I; Stenehjem A; Høieggen A Hypertension; 2014 May; 63(5):991-9. PubMed ID: 24591332 [TBL] [Abstract][Full Text] [Related]
6. Sufficient and Persistent Blood Pressure Reduction in the Final Long-Term Results From SYMPLICITY HTN-Japan - Safety and Efficacy of Renal Denervation at 3 Years. Kario K; Yamamoto E; Tomita H; Okura T; Saito S; Ueno T; Yasuhara D; Shimada K; Circ J; 2019 Feb; 83(3):622-629. PubMed ID: 30760655 [TBL] [Abstract][Full Text] [Related]
7. Individual-patient visit-by-visit office and ambulatory blood pressure measurements over 24months in patients undergoing renal denervation for hypertension. Lambert T; Gammer V; Nahler A; Blessberger H; Kammler J; Grund M; Kerschner K; Buchmayr G; Saleh K; Kypta A; Hönig S; Wichert-Schmitt B; Schwarz S; Sihorsch K; Reiter C; Steinwender C Int J Cardiol; 2015 Feb; 181():96-101. PubMed ID: 25497527 [TBL] [Abstract][Full Text] [Related]
8. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Kario K; Bhatt DL; Brar S; Cohen SA; Fahy M; Bakris GL Hypertension; 2015 Dec; 66(6):1130-7. PubMed ID: 26558819 [TBL] [Abstract][Full Text] [Related]
9. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Mahfoud F; Ukena C; Schmieder RE; Cremers B; Rump LC; Vonend O; Weil J; Schmidt M; Hoppe UC; Zeller T; Bauer A; Ott C; Blessing E; Sobotka PA; Krum H; Schlaich M; Esler M; Böhm M Circulation; 2013 Jul; 128(2):132-40. PubMed ID: 23780578 [TBL] [Abstract][Full Text] [Related]
10. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Bakris GL; Townsend RR; Liu M; Cohen SA; D'Agostino R; Flack JM; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL; J Am Coll Cardiol; 2014 Sep; 64(11):1071-8. PubMed ID: 24858423 [TBL] [Abstract][Full Text] [Related]
11. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation? Epstein M; de Marchena E J Am Soc Hypertens; 2015 Feb; 9(2):140-9. PubMed ID: 25649995 [TBL] [Abstract][Full Text] [Related]
12. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Kandzari DE; Bhatt DL; Brar S; Devireddy CM; Esler M; Fahy M; Flack JM; Katzen BT; Lea J; Lee DP; Leon MB; Ma A; Massaro J; Mauri L; Oparil S; O'Neill WW; Patel MR; Rocha-Singh K; Sobotka PA; Svetkey L; Townsend RR; Bakris GL Eur Heart J; 2015 Jan; 36(4):219-27. PubMed ID: 25400162 [TBL] [Abstract][Full Text] [Related]
13. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Townsend RR; Mahfoud F; Kandzari DE; Kario K; Pocock S; Weber MA; Ewen S; Tsioufis K; Tousoulis D; Sharp ASP; Watkinson AF; Schmieder RE; Schmid A; Choi JW; East C; Walton A; Hopper I; Cohen DL; Wilensky R; Lee DP; Ma A; Devireddy CM; Lea JP; Lurz PC; Fengler K; Davies J; Chapman N; Cohen SA; DeBruin V; Fahy M; Jones DE; Rothman M; Böhm M; Lancet; 2017 Nov; 390(10108):2160-2170. PubMed ID: 28859944 [TBL] [Abstract][Full Text] [Related]
14. Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED. Townsend RR; Ferdinand KC; Kandzari DE; Kario K; Mahfoud F; Weber MA; Schmieder RE; Pocock S; Tsioufis K; David S; Steigerwalt S; Walton A; Hopper I; Bertolet B; Sharif F; Fengler K; Fahy M; Hettrick DA; Brar S; Böhm M Hypertension; 2024 May; 81(5):1095-1105. PubMed ID: 38314554 [TBL] [Abstract][Full Text] [Related]
15. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Kario K; Mahfoud F; Kandzari DE; Townsend RR; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Brar S; Hettrick DA; Fahy M; Böhm M Hypertens Res; 2023 Jan; 46(1):280-288. PubMed ID: 36241705 [TBL] [Abstract][Full Text] [Related]
16. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. Mauri L; Kario K; Basile J; Daemen J; Davies J; Kirtane AJ; Mahfoud F; Schmieder RE; Weber M; Nanto S; Azizi M Am Heart J; 2018 Jan; 195():115-129. PubMed ID: 29224639 [TBL] [Abstract][Full Text] [Related]
17. Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN-3 trial. Yerasi C; Baker NC; Jonnalagadda AK; Torguson R; Singh S; Vies J; Waksman R J Am Soc Hypertens; 2015 Dec; 9(12):959-65. PubMed ID: 26687550 [TBL] [Abstract][Full Text] [Related]
18. 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. Azizi M; Daemen J; Lobo MD; Mahfoud F; Sharp ASP; Schmieder RE; Wang Y; Saxena M; Lurz P; Sayer J; Bloch MJ; Basile J; Weber MA; Rump LC; Levy T; Sapoval M; Sanghvi K; Rader F; Fisher NDL; Gosse P; Abraham J; Claude L; Barman NC; McClure CK; Liu Y; Kirtane AJ; JACC Cardiovasc Interv; 2020 Dec; 13(24):2922-2933. PubMed ID: 33357531 [TBL] [Abstract][Full Text] [Related]
19. Influence of pseudo-resistance on the effect of renal denervation on 24-hour ambulatory blood pressure levels. Lambert T; Nahler A; Reiter C; Gammer V; Blessberger H; Kammler J; Grund M; Saleh K; Schwarz S; Steinwender C Catheter Cardiovasc Interv; 2015 Sep; 86(3):E126-30. PubMed ID: 26033366 [TBL] [Abstract][Full Text] [Related]
20. Renal denervation in moderate treatment-resistant hypertension. Ott C; Mahfoud F; Schmid A; Ditting T; Sobotka PA; Veelken R; Spies A; Ukena C; Laufs U; Uder M; Böhm M; Schmieder RE J Am Coll Cardiol; 2013 Nov; 62(20):1880-6. PubMed ID: 23850901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]